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Abstract: Equine influenza virus remains a serious health and potential economic problem throughout
most parts of the world, despite intensive vaccination programs in some horse populations.
The influenza non-structural protein 1 (NS1) has multiple functions involved in the regulation
of several cellular and viral processes during influenza infection. We review the strategies that NS1
uses to facilitate virus replication and inhibit antiviral responses in the host, including sequestering of
double-stranded RNA, direct modulation of protein kinase R activity and inhibition of transcription
and translation of host antiviral response genes such as type I interferon. Details are provided
regarding what it is known about NS1 in equine influenza, especially concerning C-terminal
truncation. Further research is needed to determine the role of NS1 in equine influenza infection,
which will help to understand the pathophysiology of complicated cases related to cytokine imbalance
and secondary bacterial infection, and to investigate new therapeutic and vaccination strategies.
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1. Introduction
Despite intensive vaccination programs in some horse populations, equine influenza virus (EIV)
remains a serious health threat and potential economic problem throughout most parts of the world.
Since 2000, several widespread EIV outbreaks have occurred, with the global transportation of horses
responsible for introducing the virus into previously unexposed horse populations [1,2]. Equine
influenza virus is an Orthomyxovirus of the genus influenza A and is an enveloped virus with
a segmented, single-stranded, negative-sense ribonucleic acid (RNA) genome. The genome consists of
eight segments that encode at least 10 proteins: the two surface glycoproteins hemagglutinin (HA)
and neuraminidase (NA), from which the viral subtype is determined; three polymerase proteins;
a nucleoprotein; two matrix proteins; a nuclear export protein; and non-structural protein 1 (NS1).
Influenza viruses exist as genetically diverse populations, referred to as quasispecies, as a result
of the high mutation rate caused by the error-prone replication of the viral RNA-dependent RNA
polymerases [3]. The expansion of virus quasispecies provides the opportunity for viruses to evolve
and escape from the host immune response and antiviral drugs [4].
Two different subtypes of EIV have been described, but the viruses currently circulating in horses
are of the H3N8 subtype. The H3N8 subtype has diverged into two genetically and antigenically
distinct lineages: Eurasian and American [5], and the American lineage subsequently diverged further
into the Kentucky, South American and Florida sub-lineages [6]. The Florida sub-lineage has prevailed
with the emergence of two clades: clade 1 viruses predominate in America, while clade 2 viruses
predominate in Europe, but viruses of both clades have been associated with large EIV outbreaks on
other continents [7].
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Like all influenza viruses, after EIV enters the host cell, incoming viral ribonucleoproteins (vRNPs)
are transported to the nucleus where two positive-sense RNAs are generated, messenger RNA (mRNA)
and complementary RNA (cRNA) [8]. The cRNA is used as a template for producing progeny viral
RNA. The newly synthesized vRNAs are exported to the cytoplasm where new viral particles are
assembled and then exit the host cell by budding. The nuclear localization of influenza virus genome
replication is uncommon for RNA viruses [9]. The influenza non-structural protein 1 (NS1) has multiple
functions in the regulation of several cellular and viral processes during influenza infection and has
been identified as an important virulence factor [10,11]. The NS1 protein facilitates viral replication by
interfering with the host RNA processing machineries and their components by several mechanisms
as a strategy for preferential viral RNA transcription [12,13]. However, this review focuses on the
interactions of NS1 with proteins and RNA as a strategy for inhibiting cellular antiviral responses.
The NS1 protein has two distinct functional domains (Figure 1): an N-terminal RNA-binding
domain (residues 1–73) and a C-terminal “effector” domain (residues 74–230) [14,15]. The protein
structure of each domain has been determined, but the final 20–25 amino acids appear to be intrinsically
disordered. Interestingly, NS1 does not possess any intrinsic enzymatic activity. Its multifunctional
nature is explained by the presence of epitopes that interact with many different host proteins and
RNA, which is surprising for a protein that is only around 26 kDa [13]. Different epitopes bind different
molecules for different functions: heterogeneous nuclear ribonucleoprotein E1B-AP5 (1–81 aa) [16];
double-stranded RNA (dsRNA, 19–38 aa) [17]; retinoic acid-inducible gene product I (RIG-I,
38–41 aa) [18]; nuclear localization signal 1 (NLS1, 34–38 aa) and 2 (NLS2, 216–221 aa) [19]; eukaryotic
translation initiation factor 4GI (eIF4G, 81–113 aa) [12]; protein kinase R, (PKR, 123–127 aa) [20]; nuclear
export signal (NES, 137–146 aa) [21]; cleavage and polyadenylation specific factor (CPSF, 103, 106,
and 144–188 aa) [22]; poly-A binding protein II (PABPII, 223–230 aa) [23]; and (PDZ, 227–230 aa) [24].
Several other protein-binding regions are still undetermined. NS1 exists as a homodimer and both
of the functional domains contribute to the stability and dimerization of the NS1 protein, which is
essential for its multiple functions [25,26]. Different dimerization conformations of the effector domain
have been discovered and it has been hypothesized that they can occur in a strain- or ligand-specific
manner, which can contribute to the multifunctional nature of the NS1 protein [13].
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Figure 1. Predicted amino acid sequence of equine influenza strain A/equine/Uruguay/63 (H3N8)
(GenBank accession number: CY032425). The N-terminal RNA-binding domain (residues 1–73) and
C-terminal “effector” domain (residues 74–230) are indicated by the shaded bars above the amino acid
sequence (red and green, respectively), with vertical lines marking every tenth amino acid. The green
and blue text shading indicates the alpha and beta helices, respectively. The asterisk marks the
position of the 11-amino-acid truncation seen in many recent equine influenza H3N8 isolates and the
PDZ-binding domain (ESEV) is indicated in bold text.
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2. Influenza NS1 Protein Inhibition of Host Antiviral Response
Elevated inflammatory cytokine responses, such as tumor necrosis factor (TNF)-α or interleukin-6
(IL-6), have been related to the severe pathology associated with highly pathogenic influenza viruses
in humans [27,28]. Type I interferons, IFN-α and β, are produced by many different cell types during
the innate immune response to influenza virus infection and are involved in the recruitment of
inflammatory cells to the site of infection, which creates an antiviral state in the host cell to limit virus
spread and growth. IFN production is induced by recognition of pathogen-associated molecular pattern
(PAMP) receptors, which then activate the main IFN regulatory transcription factors IRF-3 and NF-κB,
which in turn transactivate IFN-β gene expression [29]. Influenza viruses have developed mechanisms
to evade these host defense mechanisms and one of the major functions of the viral NS1 protein is to
antagonize the host type I IFN response. It has been proposed that NS1 limits the production of IFN-β
both by pre-transcriptional and post-transcriptional mechanisms in a strain-dependent manner [13].
Pre-transcriptionally, NS1 prevents dsRNA- and virus-mediated activation of Interferon
Regulatory Factor 3 (IRF-3), NFκB and c-Jun/ATF-2 transcription factors [29–31]. NS1 targets the
retinoic acid-inducible gene product I (RIG-I) signaling pathway involved in the transcriptional
activation of the IFN-β gene [18]. NS1 has also been described to inhibit two IFN-inducible gene
products, protein kinase R (PKR) and 2′,5′-oligoadenylate synthetase (OAS) [17,32]. Both proteins use
dsRNA as a cofactor in their activation, and together they can impair virus replication by creating
an antiviral state within cells. The sequestering of dsRNA by NS1 has been reported to prevent their
activation [17,32]. In addition, NS1 was shown to bind PKR in a RNA-binding–independent manner
by binding with the cellular PACT protein and blocking PACT/RIG-I–mediated activation of type I
IFN [20]. Further activities of the NS1 protein include the activation of phosphoinoside-3-kinase
(PI3K) signaling, which downregulates apoptosis [33]. The four C-terminal amino acids of full-length
NS1 proteins have a canonical X[S/T]XV (where X = any amino acid) class I PDZ-binding motif
(Figure 1) [24]. PDZ domains are protein-protein recognition modules within a multitude of proteins
that organize diverse cell-signaling assemblies and it is thought that the PDZ-binding motif expressed
may have an impact on the virulence by disrupting certain cellular pathways [24].
The NS1 protein of some influenza strains is also thought to enhance pathogenicity by enabling
them to replicate despite high levels of cytokine production [13]. One study showed that replication of
an H5N1 virus strain was resistant to the antiviral effects of pro-inflammatory cytokines; this resistance
required glutamic acid at amino acid position 92 of NS1 [34].
3. What Do We Know about Equine Influenza NS1?
As the NS1 gene is more conserved than the highly variable HA, several studies have focused
on phylogenetic analysis of NS1 to provide insight into the epidemiological dynamics of influenza
viruses. Large-scale phylogenetic analyses have suggested that the equine influenza A viruses have
resulted from the direct introduction of viruses from avian hosts [35,36]. Two distinct alleles of the
NS1 gene (allele A and B) circulate in aquatic birds, the reservoir host species for all known influenza
A virus subtypes. The majority of influenza A viruses that have become established in mammalian
hosts have an NS1 that belongs to allele A [37]. An exception is A/equine/Jilin/89 (H3N8), which was
independently transmitted to horses from an avian source in an outbreak in China [38].
It appears that the HA and NS genes of equine influenza evolve in a parallel fashion, leading to
classification of NS1 into the same five groups that are used for the HA classification: the pre-divergent
lineage, the Eurasian and American-Kentucky sub-lineages, and the Florida sub-lineage clades 1
and 2 [39]. In a phylogenetic analysis of all equine influenza H3N8 subtype equine-predicted NS1
amino acid sequences currently available in the Influenza Research Database, further sub-clusters are
revealed (Figure 2). The clusters labeled I–III contain the pre-divergent strains. Cluster I includes the
prototype equine influenza A H3N8 subtype virus Miami/63 and the other three earliest equine H3N8
strains isolated in South America from 1963 to 1969. Cluster II includes pre-divergence strains isolated
between 1975 and 1980 and cluster III includes strains isolated from 1981 to 1989. Clusters IV and V
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arose as a result of divergent evolution on the Eurasian and American continents [5] and represent the
Eurasian and American-Kentucky groups, respectively. Clusters VIa and VIb represent Florida clades 2
and 1, respectively. Sequencing of the NS1 gene in addition to the HA has revealed the occurrence of
reassortment, for example the UK isolate A/equine/Lincolnshire/1/06 was a member of clade 2 of the
Florida sub-lineage according to the HA sequence but a member of the Eurasian lineage according to
the NS sequence [7].
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Florida sub-lineage viruses are distinguished by amino acid changes at positions 44, 59 and 71 in
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Pathogens 2016, 5, 57 4 of 10 
 
[5] and represent the Eurasian and American-Kentucky groups, respectively. Clusters VIa and VIb 
represent Florida clades 2 and 1, respectively. Sequencing of the NS1 gene in addition to the HA has 
revealed the occurrence of reassortment, for example the UK isolate A/equine/Lincolnshire/1/06 was 
a member of clade 2 of the Florida sub-lineage according to the HA sequence but a member of the 
Eurasian lineage according to the NS sequence [7]. 
 
Figure 2. Phylogenetic tree of equine influenza non-structural NS1 proteins. Amino acid sequences of 
77 equine influenza virus NS1 proteins were downloaded from the Influenza Research Database and 
the phylog ny inferred using Phylogeny.fr [40]. C usters of strains labeled with Roman numerals are 
described in the text. Outlier strains are individually labeled.  
Florida sub-lineage viruses ar  distinguished by amino acid changes at positions 44, 59 and 71 
in the RNA-binding domain (Figure 3A), 86 in the effector domain (Figure 3B) and 216, which lies at 
the juncture of the effector domain and the disordered C-terminal region. Florida sub-lineage viruses 
are also characterized by an 11-amino-acid truncation due to the introduction of a sto  c .  
 
Figure 3. Cart on representati  tr cture. Amino acid changes typically found in Florida 
sub-lineage viruses are indicat  i : ( ) t e A-binding domain in red (amino acid, aa44), blue 
(aa59) and green (aa71); and ( ) the effector o ain in red (aa86). Images were created using RasMol 
for Windows v2.7.5.2 and PDB files 1NS1 (A) and 3DR (B). 
Figure 3. Cartoon representations of NS1 structure. Amino acid changes typically found in Florida
sub-lineage viruses are indicated in: (A) the RNA-binding domain in red (amino acid, aa44), blue (aa59)
and green (aa71); and (B) the effector domain in red (aa86). Images were created using RasMol for
Windows v2.7.5.2 and PDB files 1NS1 (A) and 3DR (B).
Pathogens 2016, 5, 57 5 of 10
Naturally occurring NS1 proteins with C-terminal truncations of 11 to 30 amino acids due
to non-sense mutations are common in mammalian influenza viruses [13]. In addition to the
11-amino-acid truncation seen in the majority of recent equine influenza strains, three isolates in
cluster I (two isolated in Japan in 1971 and one from Algiers in 1972) have a 13-amino-acid truncation.
In general, the effect of the NS C-terminal truncation is the attenuation of the virus due to inefficiency in
blocking host gene expression, leading to higher levels of the antiviral responses such as type I IFN and
other pro-inflammatory cytokines [11,13,41,42]. Several studies have investigated the effects of NS1
truncation by constructing truncated NS1 recombinant viruses with the same backbone to minimize
variability due to the effect of differences between changes in other influenza genes among strains.
In one study, the NS1 truncation of a laboratory-adapted human influenza strain (A/WSN/33 [H1N1])
led to the increased host gene expression of inflammatory cytokines such as IL-6 and TNF-α, in human
macrophages and in mice [43]. Similarly, another study demonstrated that NS1 truncation decreased
the ability of swine influenza viruses to prevent type I IFN synthesis in pig cells [11]. Furthermore,
these mutant viruses were attenuated in vivo in pigs. Interestingly, the 2009 flu pandemic in people was
caused by a novel swine-origin H1N1 influenza virus that possessed an 11 aa C-terminal truncation in
its NS1 protein, which was associated with a higher induction of pro-inflammatory cytokine response
than human seasonal H1N1 viruses [42]. It was demonstrated that the 11 aa truncation was responsible
for inefficient blocking of host gene expression, nucleolar localization, and PABII-binding capacity
because the NSL-2– and PABII-binding domain are present at the C-terminal region of NS1 (Figure 1).
The NS1 truncation did not significantly alter virus replication in vitro or in vivo, but surprisingly
enhanced virus virulence in mice.
The original equine H3N8 isolates (Miami/63, Uruguay/63 and Sao Paulo/6/1963) have an ESEV
PDZ-binding motif at amino acids 227–230. This may reflect the recent avian origin of these strains
as ESEV is the consensus avian PDZ-binding motif [44]. All but three of the strains in cluster II
also have an ESEV motif whereas the only strain with an ESEV motif not found in cluster I or II
is A/equine/Switzerland/P112/2007, which is in cluster IV and is an example of so-called ‘frozen
evolution’ (see below). The majority of strains isolated post-divergence with full-length NS1 proteins
have an EPEV at the terminal four amino acids. A different motif is seen in five strains; four strains
isolated in the USA between 1994 and 1997 end in the sequence EPEI and one from the USA in 2003
ends in KPKI. The change in the PDZ-binding motif from ESEV to EPEV may be a result of adaptation
of the virus to a mammalian host as the motifs found in the PDZ-binding domain contribute to viral
pathogenicity in a species-dependent manner [45]. A recent study demonstrated that the ESEV motif
found in the majority of currently circulating HPAI H5N1 viruses specifically associated with the
PDZ proteins Scribble, Dlg1, MAGI-1, MAGI-2, and MAGI-3 whereas the EPEV motif did not [44].
The downstream effect of binding Scribble and Dlg1 was the disruption of cellular tight junctions in
a mammalian cell line; thus, the ESEV motif may contribute to the greater pathogenicity of an avian
virus in a mammalian host.
Several equine influenza isolates have anachronous NS1 sequences: A/equine/La Plata/88
is in cluster I as is A/equine/Essaouira/3/2004, but this strain has an EPEV motif;
A/equine/Heilongjiang/1/2010 is in cluster II with an ESEV motif; A/equine/Cheshire/1/06 is
clustered with the older American lineage strains, which were not detected in the UK since 1998;
and A/equine/Switzerland/P122/07 is clustered with older Eurasian lineage viruses. Whether these
examples of frozen evolution are a result of a reduced evolutionary rate in some circulating equine
influenza viruses or due to some or all of the gene segments of older viruses being reintroduced
into circulation (e.g., as a result of inadvertent release of the virus from a laboratory or reassortment
with a vaccine strain) is not clear. Bryant et al. (2009) suggested the latter could be the case for
A/equine/Cheshire/1/06 and A/equine/Switzerland/P122/07 as they have similar HA and NS1
gene sequences to the references strains A/equine/Newmarket/1/93 and A/equine/Sussex/89,
respectively [7].
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A recent Florida clade 1 H3N8 isolate from horses in Korea was found to have an internal deletion
of 23 bases (from 327 to 349) of the NS1, leading to a frame shift which, in addition to the C-terminal
truncation, resulted in an NS1 protein only 117 amino acids long. This virus was attenuated in cell
culture compared to A/equine/Miami/63 (full-length NS1), which was associated with increased
expression of antiviral and pro-inflammatory genes [46].
4. Potential Role of NS1 in Equine Pathology and Inter-Species Transmission
Recently, it was demonstrated that the H3N8 equine influenza virus has jumped the species barrier
to infect dogs on more than one occasion and spread among canine populations in the US [47–50].
A representative equine influenza strain with a truncated NS1 (A/equine/Newmarket/5/03)
was demonstrated to be significantly more effective at inducing type I interferon activity in
infected ponies than earlier strains (A/equine/Sussex/1989 or A/equine/Newmarket/2/93) [51].
The A/equine/Newmarket/5/03 strain was also associated with a longer duration of coughing in
horses. These factors may have influenced the ability of the recently circulating equine influenza strains
to cross the species barrier and may be linked to the truncated NS1 protein, although pathogenicity is
a highly multifactorial process with most influenza proteins playing a role.
It is unknown if equine influenza viruses could overcome species barriers such as sialic acid
receptor specificity and potentially infect people [42]. The most recent human influenza pandemic in
2009 was caused by an H1N1 strain originating from the reassortment of viruses from different species
and included gene segments of swine, human, and avian origin. It is hypothesized that polymorphisms
in NS1, including truncation and the presence of PDZ sequences, could have an important role
in virulence observed during pandemic outbreaks [13,23,42]. Although the earliest H3N8 canine
influenza viruses to be identified in Florida in 2003 and 2004 had a truncated NS1, all canine H3N8
viruses characterized since 2005 have possessed the full-length NS protein, conserving an intact PDZ
domain [52,53]. This may be an example of adaptive mutation in the NS1 gene in order to switch hosts.
Understanding the role of NS1 in the pathophysiology of influenza infection could help to manage
complicated cases. For example, secondary bacterial infection is the major cause of mortality after
primary influenza infection [54,55]. Differences in NS1 have been related to the increased production
of cytokines in humans and in horses. The cytokine dysregulation associated with previous influenza
infection is linked with secondary bacterial infection in humans, mice, and pigs [56]. Further research is
needed to investigate the role of equine influenza infection and bacterial pleuropneumonia, especially
regarding the innate immune response and virulence factors, such as NS1.
5. Potential to Apply Knowledge about NS1 for Prevention and Control of Influenza
One interesting application derived from the creation of recombinant NS1-attenuated viruses is the
development of live attenuated virus vaccines. These have the advantage of stimulating both humoral
and cell-mediated immunity. In humans and swine, NS1-attenuated viruses generated by a reverse
genetics approach have been investigated for vaccine production, with the additional advantage that
the relevant surface antigens (HA and NA) can readily be replaced in the master strain in order to
update the vaccine strains [11,57]. The effect of further C-terminal truncation of the NS1 gene of the
prototype Florida clade II strain A/equine/Kentucky/5/02 was studied using a plasmid-based reverse
genetics system to generate recombinant equine influenza viruses [58]. The truncated viruses were
attenuated in their ability to block the antiviral response, with higher amounts of IFNβ being produced
in infected cells compared to wild-type recombinant viruses. Accordingly, NS1 C-terminal truncation
led to replication attenuation of the viruses in cell and egg culture, as well as in mice [58]. Surprisingly,
the recombinant viruses with the shortest NS1 protein were the least attenuated [58]. Seronegative
horses were vaccinated with three of the NS1 truncated viruses. Horses vaccinated with one (NS1-126)
did not develop fever, had significantly fewer clinical signs and had significantly reduced quantities of
virus shedding for a shorter duration post-challenge compared to unvaccinated controls [59]. However,
reliance on the mutation of a single gene to generate an attenuated virus means that there is a risk of
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reversion to virulence or the acquisition of compensatory mutations that enable the virus to resist the
antiviral effects of pro-inflammatory cytokines.
As the NS1 protein shows less strain variation than HA and NA, it may be a better therapeutic
target for antiviral therapy [60]. Various approaches are being used to identify small molecules that
might target the interactions between NS1 and host proteins or dsRNA in order to restore the function
of innate immunity and inhibit virus replication. Further research is needed to evaluate the potential
use of these drugs, but they could be a good option for use in horses, considering the public health risk
of using antiviral drugs such as the NA inhibitor oseltamivir, where rapid development of resistance is
observed, in horses.
6. Concluding Remarks
It has been demonstrated that NS1 strain-specific differences are important in regulating host-cell
responses triggered by infection, which can lead to differences in pathology and virulence in different
species including humans, pigs, and equids. Variation in the NS1 protein occurs by various mechanisms
including truncations and deletions and reassortment. The quasispecies nature of influenza A viruses,
including EIV, may facilitate their adaptation to new hosts as variants with point mutations leading
to changes that are non-lethal to the virus but affect how the virus interacts with the host’s innate
immune response which can be rapidly selected from the quasispecies cloud. Understanding the role
of polymorphisms in equine NS1 could lead to better prediction of the likely impact of emerging
strains in the horse and other mammalian species and improve prevention and control measures.
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Abbreviations
The following abbreviations are used in this manuscript:
CPSF Cleavage and Polyadenylation Specific Factor
eIF4G eukaryotic translation initiation factor 4GI
EIV equine influenza virus
HA hemagglutinin
IFN interferon
IL interleukin
NA neuraminidase
NES nuclear export signal
NLS nuclear localization signal
NS1 non-structural protein 1
OAS 2′,5′-oligoadenylate synthetase
PABPII poly-A binding protein II.
PAMPs pathogen-associated molecular patterns
PI3K phosphoinoside-3-kinase
PKR protein kinase R
RIG-I retinoic acid-inducible gene product I
TNF tumor necrosis factor
TRIM tripartite motif
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